Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Soluble immune markers in the different phases of chronic hepatitis B virus infection.

Wiegand SB, Beggel B, Wranke A, Aliabadi E, Jaroszewicz J, Xu CJ, Li Y, Manns MP, Lengauer T, Wedemeyer H, Kraft ARM, Falk CS, Cornberg M.

Sci Rep. 2019 Oct 1;9(1):14118. doi: 10.1038/s41598-019-50729-5.

2.

Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.

Soon CF, Zhang S, Suneetha PV, Antunes DA, Manns MP, Raha S, Schultze-Florey C, Prinz I, Wedemeyer H, Sällberg Chen M, Cornberg M.

Front Immunol. 2019 Sep 4;10:2076. doi: 10.3389/fimmu.2019.02076. eCollection 2019.

3.

Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis.

Kimmann M, Tergast TL, Schultalbers M, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B.

PLoS One. 2019 Aug 2;14(8):e0220666. doi: 10.1371/journal.pone.0220666. eCollection 2019.

4.

Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis.

Tergast TL, Kimmann M, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B.

Aliment Pharmacol Ther. 2019 Sep;50(6):696-706. doi: 10.1111/apt.15439. Epub 2019 Aug 2.

PMID:
31373713
5.

The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients.

Wellhöner F, Döscher N, Tergast TL, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Maasoumy B, Wedemeyer H, Cornberg M, Pieper DH, Heidrich B.

Scand J Gastroenterol. 2019 Aug;54(8):1033-1041. doi: 10.1080/00365521.2019.1647280. Epub 2019 Jul 30.

PMID:
31361979
6.

Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.

Aregay A, Owusu Sekyere S, Deterding K, Port K, Dietz J, Berkowski C, Sarrazin C, Manns MP, Cornberg M, Wedemeyer H.

J Hepatol. 2019 Jul 8. pii: S0168-8278(19)30397-6. doi: 10.1016/j.jhep.2019.06.025. [Epub ahead of print]

PMID:
31295532
7.

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs.

Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S.

Liver Int. 2019 Jun 26. doi: 10.1111/liv.14186. [Epub ahead of print]

PMID:
31241820
8.

Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver.

Kinast V, Leber SL, Brown RJP, Vieyres G, Behrendt P, Eßbach C, Strnad P, Vondran FWR, Cornberg M, Wex C, Pietschmann T, Haybaeck J, Todt D, Steinmann E.

Cells. 2019 Jun 18;8(6). pii: E610. doi: 10.3390/cells8060610.

9.

Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.

Soon CF, Behrendt P, Todt D, Manns MP, Wedemeyer H, Sällberg Chen M, Cornberg M.

J Hepatol. 2019 Oct;71(4):673-684. doi: 10.1016/j.jhep.2019.06.005. Epub 2019 Jun 14.

PMID:
31203151
10.

Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.

Dias J, Hengst J, Parrot T, Leeansyah E, Lunemann S, Malone DFG, Hardtke S, Strauss O, Zimmer CL, Berglin L, Schirdewahn T, Ciesek S, Marquardt N, von Hahn T, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Sandberg JK, Björkström NK.

J Hepatol. 2019 Aug;71(2):301-312. doi: 10.1016/j.jhep.2019.04.009. Epub 2019 May 14.

PMID:
31100314
11.

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras.

Peiffer KH, Kuhnhenn L, Stelzl E, Dietz J, Susser S, Tal AO, Finkelmeier F, Zuckerman E, Cornberg M, Barak M, Piazzolla V, Mangia A, Zeuzem S, Kessler HH, Vermehren J, Sarrazin C.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e00060-19. doi: 10.1128/JCM.00060-19. Print 2019 Jul.

PMID:
31043467
12.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN).

J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. Review.

PMID:
30982526
13.

Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.

Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK.

HIV Clin Trials. 2018 Dec;19(6):225-234. doi: 10.1080/15284336.2018.1538193.

PMID:
30890063
14.

Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.

Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team.

Lancet Infect Dis. 2019 Mar;19(3):275-286. doi: 10.1016/S1473-3099(18)30663-7.

PMID:
30833068
15.

HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection.

Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H.

Liver Cancer. 2019 Feb;8(1):41-65. doi: 10.1159/000490360. Epub 2018 Jul 18.

16.

Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level.

Karimzadeh H, Kiraithe MM, Oberhardt V, Salimi Alizei E, Bockmann J, Schulze Zur Wiesch J, Budeus B, Hoffmann D, Wedemeyer H, Cornberg M, Krawczyk A, Rashidi-Alavijeh J, Rodríguez-Frías F, Casillas R, Buti M, Smedile A, Alavian SM, Heinold A, Emmerich F, Panning M, Gostick E, Price DA, Timm J, Hofmann M, Raziorrouh B, Thimme R, Protzer U, Roggendorf M, Neumann-Haefelin C.

Gastroenterology. 2019 May;156(6):1820-1833. doi: 10.1053/j.gastro.2019.02.003. Epub 2019 Feb 12.

17.

[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)].

Hüppe D, Serfert Y, Buggisch P, Mauss S, Böker KHW, Müller T, Klinker H, Günther R, Berg T, Cornberg M, Niederau C, Sarrazin C, Simon KG, Zeuzem S, Manns MP, Wedemeyer H.

Z Gastroenterol. 2019 Jan;57(1):27-36. doi: 10.1055/a-0821-7188. Epub 2019 Jan 14. German.

PMID:
30641600
18.

Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection.

Hengst J, Klein AL, Lunemann S, Deterding K, Hardtke S, Falk CS, Manns MP, Cornberg M, Schlaphoff V, Wedemeyer H.

J Viral Hepat. 2019 Apr;26(4):466-475. doi: 10.1111/jvh.13050. Epub 2019 Feb 1.

PMID:
30548086
19.

Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability.

Cornberg M, Tacke F, Karlsen TH; European Association for the Study of the Liver.

J Hepatol. 2019 Jan;70(1):5-7. doi: 10.1016/j.jhep.2018.10.011. Epub 2018 Nov 9. No abstract available.

PMID:
30420159
20.

A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B.

Lampertico P, Messinger D, Cornberg M, Brunetto M, Petersen J, Kennedy P, Asselah T, Rothe V, Caputo A, Bakalos G, Pavlovic V, Papatheodoridis GV.

Ann Gastroenterol. 2018 Nov-Dec;31(6):712-721. doi: 10.20524/aog.2018.0300. Epub 2018 Jul 26.

21.

Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals.

Pietsch V, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, Gebel M, Manns MP, Wedemeyer H, Potthoff A.

United European Gastroenterol J. 2018 Oct;6(8):1188-1198. doi: 10.1177/2050640618786067. Epub 2018 Jun 27.

22.

Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites.

Tergast TL, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B.

Clin Transl Gastroenterol. 2018 Sep 24;9(9):189. doi: 10.1038/s41424-018-0053-0.

23.

Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.

Attia D, Deterding K, Cornberg J, Gebel MJ, Cornberg M, Manns MP, Wedemeyer H, Potthoff A.

Eur J Gastroenterol Hepatol. 2019 Jan;31(1):67-74. doi: 10.1097/MEG.0000000000001259.

PMID:
30239347
24.

New viral biomarkers for Hepatitis B: Are we able to change practice?

Höner Zu Siederdissen C, Maasoumy B, Cornberg M.

J Viral Hepat. 2018 Nov;25(11):1226-1235. doi: 10.1111/jvh.12993. Review.

PMID:
30187603
25.

Reply to Liaw.

Höner Zu Siederdissen C, Björkström NK, Cornberg M.

J Infect Dis. 2018 Oct 20;218(11):1853-1854. doi: 10.1093/infdis/jiy396. No abstract available.

PMID:
29982785
26.

A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B.

Chan HLY, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy PT, Thompson A, Caputo A, Bakalos G, Pavlovic V, Lampertico P.

Aliment Pharmacol Ther. 2018 Sep;48(5):547-555. doi: 10.1111/apt.14862. Epub 2018 Jun 29.

PMID:
29956827
27.

Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients.

Höner Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, Gineste P, Nitcheu J, Crabé S, Stepien S, Manns MP, Trépo C, Wedemeyer H, Cornberg M.

J Infect Dis. 2018 Sep 22;218(9):1480-1484. doi: 10.1093/infdis/jiy350.

PMID:
29893893
28.

Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity.

Strunz B, Hengst J, Deterding K, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK.

Nat Commun. 2018 Jun 11;9(1):2275. doi: 10.1038/s41467-018-04685-9.

29.

[Chronic hepatitis B and D (delta) : Current and future treatments].

Wortmann N, Höner Zu Siederdissen C, Cornberg M.

Internist (Berl). 2018 Jun;59(6):519-527. doi: 10.1007/s00108-018-0432-3. Review. German.

PMID:
29761292
30.

Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.

Rinker F, Zimmer CL, Höner Zu Siederdissen C, Manns MP, Kraft ARM, Wedemeyer H, Björkström NK, Cornberg M.

J Hepatol. 2018 Sep;69(3):584-593. doi: 10.1016/j.jhep.2018.05.004. Epub 2018 Jun 29.

PMID:
29758333
31.

Systemic inflammation and immune cell phenotypes are associated with neuro-psychiatric symptoms in patients with chronic inflammatory liver diseases.

Aregay A, Dirks M, Schlaphoff V, Owusu Sekyere S, Haag K, Falk CS, Hengst J, Bremer B, Schuppner R, Manns MP, Pflugrad H, Cornberg M, Wedemeyer H, Weissenborn K.

Liver Int. 2018 Dec;38(12):2317-2328. doi: 10.1111/liv.13869. Epub 2018 Jun 12.

PMID:
29710425
32.

Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis.

Tergast TL, Wranke A, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B.

Liver Int. 2018 Sep;38(9):1602-1613. doi: 10.1111/liv.13862. Epub 2018 May 7.

PMID:
29675988
33.

Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy.

Ravens S, Hengst J, Schlapphoff V, Deterding K, Dhingra A, Schultze-Florey C, Koenecke C, Cornberg M, Wedemeyer H, Prinz I.

Front Immunol. 2018 Mar 16;9:510. doi: 10.3389/fimmu.2018.00510. eCollection 2018.

34.

Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab.

Satzger I, Ivanyi P, Länger F, Kreipe HH, Schaper-Gerhardt K, Beutel G, Cornberg M, Gutzmer R.

Eur J Cancer. 2018 Apr;93:150-153. doi: 10.1016/j.ejca.2018.01.063. Epub 2018 Feb 19. No abstract available.

PMID:
29472154
35.

Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss.

Zimmer CL, Rinker F, Höner Zu Siederdissen C, Manns MP, Wedemeyer H, Cornberg M, Björkström NK.

J Infect Dis. 2018 Apr 23;217(10):1656-1666. doi: 10.1093/infdis/jiy097.

PMID:
29471497
36.

Hepatitis B – Ein Ausblick auf aktualisierte Leitlinien.

Cornberg M.

Dtsch Med Wochenschr. 2018 Feb;143(3):183-188. doi: 10.1055/s-0043-114048. Epub 2018 Feb 6. German.

PMID:
29409090
37.

Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA?

Cornberg M, Manns MP.

Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):195-196. doi: 10.1038/nrgastro.2017.185. Epub 2018 Jan 31. No abstract available.

PMID:
29382951
38.

Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?

Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, Jäger H, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK.

HIV Med. 2018 Apr;19(4):299-307. doi: 10.1111/hiv.12579. Epub 2018 Jan 25.

PMID:
29368456
39.

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.

Marra F, Höner Zu Siederdissen C, Khoo S, Back D, Schlag M, Ouwerkerk-Mahadevan S, Bicer C, Lonjon-Domanec I, Jessner W, Beumont-Mauviel M, Kalmeijer R, Cornberg M.

Br J Clin Pharmacol. 2018 May;84(5):961-971. doi: 10.1111/bcp.13519. Epub 2018 Feb 21.

40.

Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.

Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, Port K, Manns MP, Vogel A, Cornberg M, Wedemeyer H.

Aliment Pharmacol Ther. 2018 Feb;47(4):516-525. doi: 10.1111/apt.14427. Epub 2017 Dec 4.

41.

Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up.

Schlevogt B, Deterding K, Port K, Siederdissen CHZ, Sollik L, Kirschner J, Mix C, Manns MP, Cornberg M, Wedemeyer H.

Z Gastroenterol. 2017 Sep;55(9):848-856. doi: 10.1055/s-0043-112656. Epub 2017 Sep 12.

PMID:
29186639
42.

Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?

Hupa KL, Deterding K, Port K, Kimmann M, Manns MP, Wedemeyer H, Cornberg M.

J Hepatol. 2018 Apr;68(4):851-853. doi: 10.1016/j.jhep.2017.10.035. Epub 2017 Nov 22. No abstract available.

PMID:
29175536
43.

Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.

Antunes DA, Rigo MM, Freitas MV, Mendes MFA, Sinigaglia M, Lizée G, Kavraki LE, Selin LK, Cornberg M, Vieira GF.

Front Immunol. 2017 Oct 4;8:1210. doi: 10.3389/fimmu.2017.01210. eCollection 2017.

44.

Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).

Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network.

Liver Int. 2018 May;38(5):842-850. doi: 10.1111/liv.13604. Epub 2017 Oct 26.

PMID:
28963781
45.

Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment.

Höner Zu Siederdissen C, Schlevogt B, Solbach P, Port K, Cornberg M, Manns MP, Wedemeyer H, Deterding K.

Liver Int. 2018 May;38(5):834-841. doi: 10.1111/liv.13601. Epub 2017 Oct 14.

PMID:
28960793
46.

Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study.

Maasoumy B, Bremer B, Lehmann P, Marins EG, Michel-Treil V, Simon CO, Njoya M, Cornberg M, Paxinos E, Manns MP, Vermehren J, Sarrazin C, Sohn JY, Cho Y, Wedemeyer H.

Therap Adv Gastroenterol. 2017 Aug;10(8):609-618. doi: 10.1177/1756283X17722745. Epub 2017 Aug 7.

47.

What is new on HBsAg and other diagnostic markers in HBV infection?

Höner Zu Siederdissen C, Maasoumy B, Cornberg M.

Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):281-289. doi: 10.1016/j.bpg.2017.04.009. Epub 2017 May 4. Review.

PMID:
28774410
48.

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.

Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J; FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B].

J Hepatol. 2017 Nov;67(5):918-924. doi: 10.1016/j.jhep.2017.07.012. Epub 2017 Jul 21.

PMID:
28736139
49.

Hepatitis E virus ORF 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E.

Al-Ayoubi J, Behrendt P, Bremer B, Suneetha PV, Gisa A, Rinker F, Manns MP, Cornberg M, Wedemeyer H, Kraft ARM.

Liver Int. 2018 Feb;38(2):266-277. doi: 10.1111/liv.13521. Epub 2017 Aug 20.

PMID:
28718943
50.

[Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E].

Bartenschlager R, Cornberg M, Pietschmann T.

Internist (Berl). 2017 Jul;58(7):666-674. doi: 10.1007/s00108-017-0262-8. Review. German.

PMID:
28631044

Supplemental Content

Loading ...
Support Center